Background Two types of fxed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist
(GLP-1RA) have been approved for use in type 2 diabetes. One is insulin degludec/liraglutide (iDergLira), and the other
is insulin glargine/lixisenatide (iGlarLixi). Direct comparisons between these two combination is not available.
Methods The retrospective study included 186 patients with type 2 diabetes mellitus (DM) with inadequate glycemic control on metformin and basal insulin (degludec, glargine 100, glargine 300) who were switched to fxed-ratio
combination GLP-1 RA and basal insulin. Patients were divided into two groups based on the basal insulin before
study: group I (n =86) treated with degludec were switched to iDegLira and patients group II (n =99), treated with
glargine were switched to iGlarLixi. The aim of this study was to directly compare the efects between two fxed – ratio
combination on glycemic parameters and non glycemic parameters. Follow up was 6months.
Results Mean HbA1c decreased similarly (−1.2% vs.-1.1%). Higher percentage patients in iDegLira group had
reached the HbA1c<7% after 6months (22% vs. 18.2%, p0.05). Change in body weight was signifcant in iDegLira group (1.8 kg vs. 0.7 kg,
p<0.001). At the end of the study patients showed decrease in total cholesterol (TC) and low-density lipoprotein
(LDL) for 0.2mmol/L in iDegLira, 0.1mmol/l in iGlarLixi, triglycerides decreased 0.3mmol/l in both groups, high-density lipoprotein(HDL) increased 0.1mm/l in iGlarLixi.
Conclusion Our results showed that more patients with iDegLira had HbA1c less than 7% and these combination had better efect on weight loss. There was no diference observed in FPG and PPG, lipid profle and rate of
hypoglycemia.
